Although different types of immunotherapies for LC have proven to be challenging, PD-1 (programmed cell death 1) blockade, an immune checkpoint blockade strategy, has demonstrated promising therapeutic responses [6]. The gene discussed is PDCD1; the disease is laryngotracheoesophageal cleft.